P53-Armed Oncolytic Virotherapy Promotes the Efficacy of PD1 Blockade in Murine Osteosarcoma Tumors
Authors:
Open Access
- 30 December 2025
- journal article
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46 (1) , 69-84
Abstract
Background/Aim: Osteosarcoma (OS) is refractory to immune checkpoint inhibitors targeting programmed cell death 1 (PD1)/PD ligand 1 (PD-L1) due to poor immune response. We previously developed telomerase-specific, replication-competent oncolytic adenoviruses non-armed OBP-301 and P53-armed OBP-702 that exert antitumor efficacy against human OS cells. Recently, we demonstrated that P53-armed OBP-702 induces more profound immunogenic cell death and antitumor immune response against human and murine OS cells than does non-armed OBP-301. In the present study, we assessed the combined efficacy of PD1 blockade and P53-armed OBP-702 against murine OS cells. Materials and Methods: Three murine OS cell lines (K7M2, NHOS, NHOS-LM4) were used to assess the cytopathic effect of non-armed OBP-301 and P53-armed OBP-702 by XTT assay. Virus-induced immunogenic cell death was assessed by analyzing the levels of extracellular adenosine triphosphate and high-mobility group box protein B1. The expression of PD-L1 and PD-L2 was analyzed by flow cytometry. The malignant potential of NHOS-LM4 cells was analyzed by a migration and invasion assay. An orthotopic NHOS-LM4 tumor model was used to evaluate the antitumor efficacy of combination therapy with P53-armed OBP-702 and anti-PD1. Results: P53-armed OBP-702 exhibited antitumor potential for the induction of immunogenic cell death, apoptosis, autophagy, and PD-L1/2 upregulation in K7M2 and NHOS cells. NHOS-LM4 cells showed increased migratory and invasive ability compared to NHOS cells. P53-armed OBP-702 significantly suppressed the malignant potential of NHOS-LM4 cells. Combination dosing showed that P53-armed OBP-702 significantly promoted the antitumor effect of PD1 blockade against NHOS-LM4 tumors. Conclusion: Our results suggest that P53-armed OBP-702 is a promising agent for improving the antitumor effect of PD1 blockade in treating invasive OS.Keywords
This publication has 40 references indexed in Scilit:
- The generation and use of animal models of osteosarcoma in cancer researchGenes & Diseases, 2024
- Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcomaMolecular Therapy-Oncolytics, 2021
- Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expressionCancer Chemotherapy and Pharmacology, 2021
- International trends in incidence of osteosarcoma (1988‐2012)International Journal of Cancer, 2021
- Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trialCancer Immunology, Immunotherapy, 2021
- Crosstalk between oncolytic viruses and autophagy in cancer therapyBiomedicine & Pharmacotherapy, 2021
- Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcomaCancer Immunology, Immunotherapy, 2020
- Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC studyEuropean Journal of Cancer, 2019
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer TherapyCancer Cell, 2015
- A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppressionEuropean Journal of Cancer, 2012